Feature

How to recognize and treat hidden inflammation


 

Glucocorticoids and immunosuppressants

Despite therapeutic intervention, the disease can have a fatal outcome, even if the patient is young, said Dr. Müller-Ladner. Glucocorticoids are the current therapy of choice. The dose is more than 0.5 mg of prednisolone equivalent per kg of body weight. “This usually leads to a rapid improvement in the inflammation. Subsequently, every organ is thoroughly diagnosed to assess the severity of the disease and to plan further treatment steps.”

In the long term, proven immunosuppressants, such as azathioprine, mycophenolate, leflunomide, and methotrexate, can be used, just as for many other chronic inflammatory diseases. Cyclophosphamide or cyclosporine is used more rarely, owing to their side effect profiles.

Because of the B-cell dominance, B-cell–depleting therapy with rituximab is currently a highly effective therapeutic option but one that must be applied for, because such use is off label. “If the body responds well to the medication, organ function often recovers,” said Dr. Müller-Ladner.

This article was translated from the Medscape German edition. A version appeared on Medscape.com.

Pages

Recommended Reading

Sarilumab effective for polymyalgia rheumatica in phase 3 trial
MDedge Family Medicine
Vaccination cuts long COVID risk for rheumatic disease patients
MDedge Family Medicine
Abnormal bleeding common among youth with joint hypermobility
MDedge Family Medicine
Belimumab for pregnant women with lupus: B-cell concerns remain
MDedge Family Medicine
Best estimates made for hydroxychloroquine retinopathy risk
MDedge Family Medicine
VEXAS syndrome: More common, variable, and severe than expected
MDedge Family Medicine
75 years: A look back on the fascinating history of methotrexate and folate antagonists
MDedge Family Medicine
Two biomarkers identify high-risk lupus nephritis
MDedge Family Medicine
Health plans get very poor scores for access to autoimmune drugs
MDedge Family Medicine
New tool better estimates cardiovascular risk in people with lupus
MDedge Family Medicine